Cargando…

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

It is unknown if the cardioprotective and renal effects of glucagon‐like peptide‐1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leiter, Lawrence A., Bain, Stephen C., Bhatt, Deepak L., Buse, John B., Mazer, C. David, Pratley, Richard E., Rasmussen, Søren, Ripa, Maria Sejersten, Vrazic, Hrvoje, Verma, Subodh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496251/ https://www.ncbi.nlm.nih.gov/pubmed/32372454 http://dx.doi.org/10.1111/dom.14079

Ejemplares similares

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
por: Verma, Subodh, et al.
Publicado: (2021)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
por: Crowley, Matthew J., et al.
Publicado: (2020)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018)

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
por: Jensen, Anders Boisen, et al.
Publicado: (2023)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
por: Witkowski, Michal, et al.
Publicado: (2018)

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial
por: Tack, Cees J., et al.
Publicado: (2019)

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs
por: Witkowski, Michal, et al.
Publicado: (2018)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2019)

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
por: Leiter, Lawrence A., et al.
Publicado: (2019)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
por: Masmiquel, L., et al.
Publicado: (2016)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
por: Petrie, John R., et al.
Publicado: (2016)

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
por: Buse, John B, et al.
Publicado: (2023)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_af4fm151gr4au3nq7cig0s62gh